Cilo Cybin Holdings’ interim losses mainly the result of corporate initiatives

CILO CYBIN Holdings’ share price fell sharply by 7.1% on Friday after its interim results showed a taxed loss of R212.2 million versus a R6m profit previously - the losses were mainly driven by accounting listing charges.

- EDWARD WEST

GABRIEL Theron, the CEO and founder of Cilo Cybin.

(SUPPLIED)

“Excluding the once-off IFRS 2 (listing) charge, the group would have ended on a profit of R5m,” the interim results said on Friday.

The share price ended at R2.85 when the market closed.

A non-cash IFRS 2 listing expense of R217.5m was recognised, arising from the reverse acquisition and the issue of shares to acquire the listing status of Cilo Cybin.

Cilo Cybin is South Africa's first licensed medical cannabis cultivator and remains one of the few vertically integrated players with both cultivation and manufacturing licences.

It operates as a contract manufacturer for the cannabis industry, supplying GMP bulk APIs (active pharmaceutical ingredients) to both local and international markets.

The results reflected its performance following the completion of the acquisition of Cilo Cybin Pharmaceutical, the effective date of which was September 30, 2025.